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Diabetic retinopathy (DR) is the leading cause of blindness among the American working population. The purpose of this study is
to establish a new diabetic animal model using a cone-dominant avian species to address the distorted color vision and altered cone
pathway responses in prediabetic and early diabetic patients. Chicken embryos were injected with either streptozotocin (STZ), high
concentration of glucose (high-glucose), or vehicle at embryonic day 11. Cataracts occurred in varying degrees in both STZ- and
high glucose-induced diabetic chick embryos at E18. Streptozotocin-diabetic chicken embryos had decreased levels of blood insulin,
glucose transporter 4 (Glut4), and phosphorylated protein kinase B (pAKT). In STZ-injected E20 embryos, the ERG amplitudes
of both a- and b-waves were significantly decreased, the implicit time of the a-wave was delayed, while that of the b-wave was
significantly increased. Photoreceptors cultured from STZ-injected E18 embryos had a significant decrease in L-type voltage-gated
calcium channel (L-VGCC) currents, which was reflected in the decreased level of L-VGCC𝛼1D subunit in the STZ-diabetic retinas.
Through these independent lines of evidence, STZ-injection was able to induce pathological conditions in the chicken embryonic
retina, and it is promising to use chickens as a potential new animal model for type I diabetes.
1. Introduction
Diabetes is a fast-growing global problem, and diabetic
retinopathy (DR) is the leading cause of blindness among
Americans over 40-year old [1–3]. Nearly all patients with
type 1 diabetes and more than 60% of those with type 2
diabetes will develop DR [4–6]. Diabetic retinopathy is a
dual disorder with microvascular complications and retinal
degeneration [7] with a projected prevalence of more than
11 million patients by 2030 in the USA [8]. Historically, DR
has been investigated and treated as a complication of retinal
vasculature [7]. However, recent developments of highly
sensitive techniques, such as multifocal ERG [9] show that
the retina starts to degenerate in early diabetes [7, 10] prior
to clinical signs of DR and any vascular complications. The
distorted color vision and altered cone pathway responses,
including the delayed ERG a-wave implicit time, are among
the first clinical signs in early stage diabetic patients without
DR [11–13], indicating that the cone photoreceptors are
compromised in early diabetes [11–13]. In humans, diabetes
causes dysfunction [14] and loss of the blue-light sensitive S-
cones [11, 14–16]. In hyperglycemic animals with DR, cone
photoreceptor degeneration is the predominant dysfunc-
tion [7]. Therefore, it is critical to understand how cone
photoreceptors are altered under early diabetic states, so
that potential therapeutic or preventive treatments could be
developed.
There are various DR models from dogs, rodents, to
zebrafish [7].While these animalmodels have certain charac-
teristic diabetic phenotypes, none are without limitations [7,
17]. It takes 3–5 years to develop DR lesions after induction of
diabetes in dogs [17]. Streptozotocin- (STZ-) induced diabetic
rats or mice show similar signs of early DR to that of humans.
Thus, the rodentmodels are themost usedDRanimalmodels.
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However, certain biochemical changes, ganglion cell apopto-
sis, or signs of Mu¨ller cell reactivity are inconsistent between
STZ-induced diabetic rats and mice [17]. Rodent retinas do
not have a macula. As such, they cannot serve as an adequate
model of diabetic macular edema that happens in humans
[17]. Chronic inflammation associatedwith diabetes is known
to contribute to DR [18], but the genomic responses in mouse
models poorly mimic human inflammatory diseases [19].
While one major advantage of using mice in research is for
their genetic manipulations, some wild-type mouse strains
harbor preexisting abnormal retinas [20]. Furthermore, the
rod-dominant nocturnal retinas might not be the best model
to address the dysfunction and apoptosis of cones in human
DR. Hence, there is a need to develop new diabetic animal
models that will complement the current animal models and
address certain aspects of human DR.
Chickens have yet to become a widely used animal model
for human disease research mainly because they are not
mammalian, and their genetic makeup is ∼70% homologous
to humans. While the methods to produce transgenic birds
have been developed, it is still more technically challenging
to generate transgenic chickens compared to the making
of stable transgenic mouse lines [21]. However, chickens
are diurnal with complex color vision, just like humans.
Spontaneous mutant blind chickens have been used recently
as a model for photoreceptor-degenerative blindness [22].
The fact that the chicken retina is cone-dominant makes it
a suitable candidate to study human cone photoreceptor-
related degenerative diseases. Also, the abundance of retinal
tissue per eye in chickens allows for molecular and biochem-
ical assays without sacrificing or pooling large numbers of
animals. While STZ successfully induces diabetes in dogs,
rats, and mice, it fails to induce diabetes in adult birds
[23], mainly due to species-dependent susceptibility to STZ
in the pancreas islets [24]. Interestingly, cultured human
islets are also highly resistant to STZ [24, 25]. In order to
successfully induce diabetes in chickens, we took advantage
of the fact that the pancreas is not fully developed in
chicken embryos [26], but cone photoreceptors are functional
during the late embryonic stages [27–30]. We injected STZ
into the amnion layer in ovo and successfully induced type
1 diabetes. Here, we present morphological, physiological,
and molecular evidence of our newly established chicken
model that is comparable to the existing rodent diabetic
retinopathy models. Our new diabetic model using cone-
dominant chickens is complementary to the existing rodent
models, which will allow researchers to address how early
diabetic insults cause cone dysfunction and apoptosis and
allow for potential treatments in the future.
2. Materials and Methods
2.1. Preparation of STZ and High Concentrations of Glucose.
A sodium citrate buffer solution (citric buffer; 10mM, pH
4.0) was prepared to dissolve STZ and served as the vehicle.
Streptozotocin (STZ; Enzo Life Sciences; Farmingdale, NY,
USA) was prepared freshly and dissolved in the citric buffer
at 50mg/mL. Glucose was dissolved in distilled water at
250mg/mL as a stock solution and stored at −80∘C for up
to one month. Prior to injections, the STZ or glucose stock
solution was filtered through a 0.22 𝜇m syringe filter. Various
doses of STZ or glucose were injected into fertilized eggs
based on the weight of the whole egg (STZ, ranging from 250
to 300mg/kg-egg weight; glucose, 2500 or 3000mg/kg-egg
weight). The volume of each injection was between 250 and
350 𝜇L per egg.
2.2. In Ovo Injections and Maintenance of Chick Embryos.
Fertilized eggs (Gallus gallus, Single Comb White Leghorn)
were obtained from the Poultry Science Department, Texas
A&M University (College Station, TX, USA). All chicken
embryos were maintained at 39∘C ± 0.5∘C. At embryonic day
8 (E8), chick embryos were kept in incubators equipped with
lights and timers programmed for 12 : 12 h cyclic light-dark
cycles. At E12, the in ovo injection procedures were carried
out in a sterilized culture hood. Eggs were placed air-sac up
and first cleaned with 70% ethanol. A small window (less
than 2 cm2) on the shell above the air-sac was opened, and
the shell membrane was carefully peeled away. The injection
needle penetrated through the membrane layers without
breaking blood vessels. The vehicle, STZ, or glucose solution
(0.25–0.3mL) was injected into the amnion layer, which was
directly outside of the embryos, with a 30G needle during
the “light phase” of incubation. After the injection, the small
shell opening was covered with two pieces of medical tape
to prevent infections. Injected embryos were then returned
to the light programmed incubators. At E18–E20, the chick
embryos were harvested for various analyses including his-
tological sections, Western immunoblotting, patch-clamp
recordings of L-type voltage-gated calcium channels, and
electroretinograms (ERGs).
2.3. Histology and Nissl Staining. Intact chicken eyes were
submerged and fixed with Zamboni fixative (Newcomer
Supply, Middleton, WI, USA) overnight at 4∘C, followed
by several washes in phosphate buffer (0.1M PB, pH 7.4)
and transferred to 10%, 20%, and 30% sucrose-PB solution
for cryoprotection. The whole eye was sectioned at 12 𝜇m
thickness and further processed for Nissl staining. After
dehydration, coverslips were mounted, and images were
observed and taken under a Zeiss microscope.
2.4. Plasma Glucose and Insulin Detections. Blood from
E18 hearts was collected for blood glucose and insulin
levels. A glucometer (Clarity Plus, Diagnostic Test Group,
Boca Raton, FL, USA) was used to measure blood glucose
levels. For insulin detection, blood samples (200–300𝜇L
per embryo) were stored overnight at 4∘C to separate the
serum from blood cells. Serum portions were collected
by centrifugation (15min; 2000 g). Serum insulin detection
was detected using a chicken insulin ELISA kit (Cusabio,
San Diego, CA, USA), which has higher sensitivities for
chicken insulin than the regular insulin ELISA kits made
for rodents or humans. The procedure was provided by
the manufacturer. Results were analyzed against a standard
curve.
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2.5. Western Immunoblot Analysis. Retina tissue samples
were collected and prepared as described previously [31].
Briefly, intact retinas were homogenized in a Tris lysis
buffer including (in mM): 50 Tris, 1 EGTA, 150 NaCl, 1%
Triton X-100, 1% 𝛽-mercaptoethanol, 50 NaF, and 1 Na
3
VO
4
;
pH 7.5. Samples were separated on 10% sodium dodecyl
sulfate-polyacrylamide gels by electrophoresis and trans-
ferred to nitrocellulose membranes. The primary antibodies
used in this study were anti-glucose transporter 4 (anti-
Glut4; Cell Signaling Technology, Danvers, MA, USA), anti-
phosphorylated protein kinase B (AKT) at thr 308 (anti-
pAKT-thr308; Cell Signaling Technology), anti-VGCC𝛼1D
(Alomone, Jerusalem, Israel), and anti-ERK (total ERK,
used for loading control; Santa Cruz Biochemicals, Santa
Cruz, CA, USA). Blots were visualized using appropriate
secondary antibodies conjugated to horseradish peroxidase
(Cell Signaling Technology) and an enhanced chemilumines-
cence (ECL) detection system (Pierce, Rockford, IL, USA).
Relative protein expressions for all proteins involved in this
study are reported as a ratio to total ERK. Band intensities
were quantified by densitometry using Scion Image (NIH,
Bethesda, MD, USA). All measurements were repeated at
least 3 times.
2.6. Electroretinogram. At E20, chick embryos were anes-
thetized with an in ovo injection of 250 𝜇L tribromoethanol
(Avertin) solution (12.5mg/mL) into the amnion. The shell
window was widened to expose the head, but the body was
left in the egg to maintain body temperature. A small cut
was made on the eye lid and the nictitating membrane to
expose the cornea. The ground electrode was placed on top
of the head, the reference electrode was placed under the
skin in the cheek area, and the threaded recording electrode
conjugatedwith amini contact lens (OcuScience,Henderson,
NV, USA) was placed on the surface of the cornea. A drop of
Goniovisc (Hub pharmaceuticals, Rancho Cucamonga, CA)
was applied on the surface of the cornea to keep it moist
and to maintain proper contact between the cornea and the
recording electrode. A portable ERG device (OcuScience)
was used for the ERG recordings. Since we only focused
on cone photoreceptor function, the photopic ERG was
recorded.The chick embryo was adapted to 30,000mcd⋅s/m2
background light for 10min and exposed to 32 flashes (0.5 s
interval) at 3000mcd⋅s/m2 light intensity.The amplitudes and
implicit time of a- and b-waves were recorded and analyzed
using the ERGView 4.4 software (OcuScience). Throughout,
egg temperature was maintained at 39∘C using a custom-
made digital temperature controller with a flexible heating
tape (Briskheat, Columbus, OH, USA) surrounding the egg.
2.7. Dissociated Retinal Cultures and Electrophysiology. Reti-
nas from E18 embryos were dissected, dissociated, and
cultured on poly-D-lysine coated coverslips overnight in the
presence of 20 ng/mL ciliary neurotrophic factor (CNTF,
R&D Systems, Minneapolis, MN, USA) and 10% heat-
inactivated horse serum as described previously [30, 32].
The cell culture incubator was maintained at 39∘C and
5% CO
2
. Whole cell patch-clamp configuration of L-type
voltage-gated calcium channel (L-VGCC) current recordings
on cone photoreceptors was carried out using mechanically
ruptured patches. The external solution was (in mM): 110
NaCl, 10 BaCl
2
, 0.4 MgCl
2
, 5.3 KCl, 20 TEA-Cl, 10 HEPES,
and 5.6 glucose, pH 7.35 with NaOH. The pipette solution
was (in mM): 135 Cs acetate, 10 CsCl, 1 NaCl, 2 MgCl
2
, 0.1
CaCl
2
, 1.1 EGTA, and 10 HEPES, pH 7.3 adjusted with CsOH.
Recordings were made only from cells with elongated cell
bodies with one or more prominent oil droplets (hallmark
of avian cone photoreceptors) [27, 28, 33]. Currents were
recorded at room temperature (23∘C) using an Axopatch
200B (Molecular Devices, Union City, CA, USA) or A-M
2400 amplifier (A-M Systems Inc., Carlsborg, WA, USA).
Signals were low-pass filtered at 2 kHz and digitized at 5 kHz
with Digidata 1440A interface and pCLAMP 10.0 software
(MolecularDevices). Electrode capacitancewas compensated
after gigaohm seals were formed. Cells were held at −80mV,
and current-voltage (I-V) relations were elicited from the
holding potential in 200ms steps (5 s between steps) to
test potentials over a range of −80 to +20mV in 10mV
increments. The maximal currents were obtained when the
steps depolarized to 0∼+10mV. The membrane capacitance,
series resistance, and input resistance of the recorded pho-
toreceptors were measured by applying a 5mV (100ms)
depolarizing voltage step from a the holding potential. Cells
with an input resistance smaller than 1GΩ were discarded.
The membrane capacitance reading was used as the value
for whole cell capacitance. The current densities (pA/pF)
were obtained by dividing current amplitudes by membrane
capacitances. Leak currents were subtracted manually after
data acquisition.
2.8. Statistics. All of the data are presented as mean ± s.e.
(standard error). Student’s t-test was used to compare the
control and STZ-induced diabetic groups. One-way ANOVA
followed by Tukey’s post hoc test for unbalanced n was used
for comparisons of multiple groups. Throughout, ∗𝑃 < 0.05
was regarded as significant.
3. Results and Discussion
3.1. Successful Induction of Diabetes in Chicken Embryos.
We first had to determine the best way to induce diabetes
in chicken embryos through in ovo injections of STZ or
high concentrations of glucose (high glucose). We originally
injected STZ into the embryos directly, but the toxicity of
STZ persistently killed the embryos. After testing several
injection sites external to the embryo (amnion layer, allantois,
albumen, and yolk sac), we discovered that injecting the
amnion layer at embryonic day 12 (E12) gave us the best
outcome, in which the survival rate was higher than direct
injections into the embryos (Table 1), as well as success-
ful induction of hyperglycemia by E18 (Figure 1(a)). We
tested three different doses of STZ (300, 275, and 250 mg
per Kg of egg weight [mg/kg-egg]) and two for glucose
(3,000 and 2,500mg/kg-egg). One week after injections,
both STZ- and high glucose-injected embryos displayed a
significant increase of plasma glucose levels (Figure 1(a)), and,
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Table 1:The numbers and rates of death and cataract after various STZ or high-glucose injections. Various doses of STZ or high-glucose were
injected into the chick embryos at E11, and the data were taken at E18.
Group Total(number)
Survival
(number)
Death
(number)
Cataract
(number)
Death rate %
(death/total)
Cataract rate %
(Cataract/Survival)
Control 61 56 5 3 8% 5.4%
STZ 300mg/kg-egg 46 37 9 32 19.6% 86.4%
STZ 275mg/kg-egg 21 16 5 9 23.4% 56.2%
STZ 250mg/kg-egg 22 15 7 5 31.8% 30%
Glucose 3000mg/kg-egg 23 6 17 3 74% 50%
Glucose 2500mg/kg-egg 9 7 2 3 22.2% 41.8%
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Figure 1: STZ- or high glucose-injected embryos have elevated plasma glucose levels without changes in body weights. (a) At E12, embryos
were injected with either STZ (300, 275, or 250), high glucose (3,000 or 2,500)mg per kg of egg weight (mg/kg), or vehicle (control). All STZ-
and high glucose- injected embryos at E18 had significantly higher plasma glucose levels compared to the control (CON). (b) There is no
statistical difference in body weight among all groups. ∗𝑃 < 0.05. n.s.: no statistical difference.
thereafter, we used hyperglycemia as an index of successfully
induced diabetes in chicken embryos. Even though the high
glucose injections elicited higher levels of hyperglycemia
(Figure 1(a)), they also caused a higher overall death rate
compared to the STZ injections (Table 1). However, there
was no significant change in embryo body weight after STZ
or high glucose injection compared to the controls (injected
with the vehicle; Figure 1(b)). If we had observed any major
body weight changes after 1 week of STZ or high glucose
injections, it might reflect that STZ or high glucose injections
had compromised the global development of the chicken
embryos.
In addition, we also observed cataracts in STZ- and high
glucose-injected embryos (Table 1 and Figure 2(a)). In the
USA, about 24% of patients with early onset diabetes (mainly
type I) suffer from cataracts [34]. Similarly, cataracts occur in
STZ-induceddiabetic rats [35]. STZ- or high glucose-induced
cataracts to varying degrees but always at a significantly
higher rate compared to those that arise spontaneously in
normal chicken embryos. While we observed cataracts in
both STZ and hyperglycemia-induced diabetic eyes, STZ
injections apparently induced cataracts at a higher rate
than hyperglycemia-induced diabetic eyes with injections of
STZ at 300mg/kg-egg inducing the highest rate of cataract
(Table 1). We cannot rule out the possibility of chemical
damage by STZ in chicken embryos. Both STZ and high
glucose injections caused retinal degeneration, as shown in
Figure 2(b) where overall retina thickness was decreased
compared to the control, but the degree of change in retinal
thickness varied.Therefore, the morphological data provided
evidence that injections of STZ or high glucose were able
to induce diabetic retinas in chicken embryos. One concern
with the high glucose treatment was the apparent dramatic
difference in retinal thickness from the control and STZ-
injected groups. It could be due to the effect of high glucose
during retinal development, even though the survival rate of
the 2500mg/kg glucose treatment seemed to be acceptable
(Table 1). Taking all factors into consideration, including the
survival of embryos, the occurrence of cataract, general reti-
nal morphology, and hyperglycemic index, we determined
Journal of Diabetes Research 5
Control
Diabetes
(a)
High glucoseSTZControl
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Figure 2: There are morphological changes in STZ- and high glucose-induced diabetic eyes. (a) Cataracts (arrows) occur in STZ- or high
glucose-induced diabetic embryos at E18. (b)The retinas of STZ- and high glucose-induced diabetic eyes are thinner than the control eyes of
the same age (E18).
that the best strategy to induce diabetes in chicken embryos
was a single injection of STZ at 300mg/kg-egg into the
amnion layer. Hence, we focused on the characterizations
of STZ-induced diabetic chicken embryos in the following
analyses.
3.2. Molecular Markers of STZ-Induced Diabetic Chicken
Embryos. Streptozotocin is known to deplete whole body
insulin and induce diabetes in animals by destroying pan-
creatic beta-cells [36–38]. We used an ELISA-based assay kit
to detect blood insulin levels (Figure 3(a)). Even though the
embryonic pancreas is not fully developed, insulin-positive
pancreatic cells are present in chicken embryos from E10
[26]. At E18, blood insulin level was low in the control group
but was significantly decreased in STZ-injected embryos
(Figure 3(a)).
We next examined several molecular markers that are
linked to insulin signaling and changed under diabetic
conditions. We found that one week after STZ injections
both Glut4, the dominant glucose transporter in the retina,
and phosphorylated AKT at thr308 (pAKTthr308) were sig-
nificantly decreased in the E18 diabetic retina (Figure 3(b)),
similar to previous reports in STZ-induced diabetic rats [39–
45]. Hence, results from these molecular markers provide
evidence that STZ injections were able to induce diabetic
retinas in chicken embryos.
3.3. Physiological Evidence for STZ-Induced Diabetic Retina in
Chicken Embryos. In STZ-induced diabetic rats, the ampli-
tudes of ERG a- and b-waves are decreased, and the implicit
times for both are increased compared to the control [35, 46].
In humans, early diabetic patients without DR have delayed
ERGa-wave implicit time in cone responses [12, 13, 16, 47, 48].
We found that 9 days after injections (ERGs recorded at
E20), STZ-injected embryos had significant decreases in the
amplitudes of both photopic ERG a- and b-waves but with a
significant increase in the b-wave implicit time compared to
the control (Figure 4(a)). We performed ERG recordings on
13 STZ-injected embryos, but 5 completely had no currents,
while all controls (𝑛 = 8) displayed ERGs (Figure 4(a)).
Hence, we only included the 8 STZ-injected embryos that had
reputable ERG waveforms in our statistical comparison.
Since L-type voltage-gated calcium channels (L-VGCCs)
are responsible for neurotransmitter release from photore-
ceptors and bipolar cells [49], we cultured photoreceptors
from E18 embryos and used patch-clamp recordings to assess
whether the changes in ERGs correspond to any alteration
in L-VGCCs. We found that, starting at −40mV step voltage,
photoreceptors obtained fromSTZ-injected embryos had sig-
nificant decreases in L-VGCC current densities (Figure 4(b)),
and Western blot analyses showed that these embryos had a
significant decrease in the protein level of the L-VGCC𝛼1D
subunit (Figure 4(c)), the major L-VGCC𝛼1 subunit in cone
photoreceptors [50–53]. Therefore, physiological data from
both ERGs and patch-clamp recordings display our ability to
induce diabetic retinal degeneration in chicken embryos by
STZ injections.
4. Conclusions
In humans, cone photoreceptors are compromised in early
diabetes prior to DR, and, currently, there is no treatment or
cure to revert degenerated photoreceptors back to prediabetic
states. Current animal models for DR research mostly use
rod-dominant animals, which prompted us to establish a
cone-dominant animal model to address cone dysfunction in
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Figure 3: STZ-injected embryos display changes in biomarkers that are characteristic to diabetes. (a) Blood insulin from STZ-injected
embryos (E18) is significantly lower than the control (injected with vehicle). (b) The protein levels of glucose transporter 4 (Glut4) and
phosphorylated AKT at thr308 (pAKTthr308) are significantly lower in the STZ-induced diabetic retinas compared to the control.
prediabetic or early diabetic conditions. Our results indicated
that STZ injections into the amnion layer in ovo induced
diabetic pathology in chicken embryos. We compared the
death and cataract rates between STZ- and high glucose-
induced diabetes (Table 1) and determined that a single injec-
tion of STZ at 300mg/kg-egg weight induced the best result
with a lower death rate but higher incidence of cataracts. We
then further looked for STZ-induced changes in biomarkers
and retinal physiology. As cataracts are a hallmark of early
onset type I diabetes in humans, our model might be suitable
for type I diabetes research. In agreement with the rodent
models, Glut4 and pAKT were decreased in the diabetic
retinas. Intracellular phosphoinositol 3 kinase (PI3K) AKT
signaling is important for cell growth, metabolism, and
survival [54] and is essential for insulin-mediated glucose
uptake and maintaining normal glycemia [55–57]. Insulin
activates intracellular Glut trafficking from the cytosol to the
plasma membrane, mediated by PI3K-AKT signaling, and
insertion of Glut into the plasma membrane facilitates cellu-
lar glucose intake [58–61]. Glucose is themajor energy source
for neurons in the retina and brain [62–64]; thus, PI3K-AKT
mediated Glut trafficking is essential for neuron survival.The
dominant Glut present in the retina is the type 4 (Glut4).The
decreases of Glut4 and pAKT in the STZ-diabetic chicken
retina confirmed that STZ injections into chicken embryos
successfully induced pathological conditions in early diabetic
retina.
We further established a stable ERG recording method
from anesthetized chick embryos with body temperature
maintained at 39∘C. We performed all ERG recordings from
E20 instead of E18 because E20 embryos gave us more
reliable ERG recordings. Since our purpose in this study was
to establish a cone-dominant diabetic retinopathy animal
model, we only performed ERG recordings with the light-
adapted photopic responses. We found that both a- and
b-wave amplitudes were significantly decreased in STZ-
injected embryos. The implicit times of both a- and b-
wave from STZ-injected embryos were also delayed, with a
significant increase on the b-wave implicit time compared
to the control. Our ERG results echo those from human
patients where cone pathway responses are weakened in
early diabetic patients [9, 10, 13, 46, 47]. Since L-VGCCs are
responsible for synaptic transmission from photoreceptors,
the ERG results were consistent with our finding that cones
cultured from STZ-injected embryos had significantly lower
amplitudes of L-VGCC currents, which coincides with the
significant decrease of L-VGCC𝛼1D expression in the STZ-
injected retina compared to the control. Our patch-clamp
recording of L-VGCCs from cultured cone photoreceptors
was the first to indicate that diabetic conditions might
severely impact the expression and plasma insertion of L-
VGCCs.We previously showed that PI3K-AKT is responsible
for L-VGCC𝛼1 subunit trafficking and insertion into the
plasma membrane in cone photoreceptors [32]. Hence, the
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Figure 4: The STZ-induced diabetic retina exhibits changed physiology. (a1-a3) ERGs were recorded from E20 embryos. (a1) Representative
ERGwaveforms froma control and a STZ-injected embryo. (a2)The amplitudes of a- and b-waves fromSTZ-injected embryos are significantly
lower than the ones recorded from controls. (a3) The implicit time of both a- and b-waves from STZ-injected embryos are delayed, but there
is a significant increase of the b-wave implicit time from STZ-injected embryos compared to the control. (b1-b2) Cone photoreceptors from
control and STZ-injected embryonic retinas were dissociated and cultured at E18. The next day, patch-clamp recordings of L-VGCCs were
carried out. (b1)The average data of voltage (mV) current density (pA/pF) relationship from the control and STZ-diabetic photoreceptors are
shown. (b2) At both −40mV and 0mV, the L-VGCC current densities are significantly lower from STZ-diabetic photoreceptors compared to
the control. (c) The STZ-injected diabetic retina has a significant decrease in the protein level of the L-VGCC𝛼1D subunit compared to the
control. Total ERK serves as a loading control. ∗𝑃 < 0.05.
decrease of phosphorylation/activity of PI3K-AKT [39, 58] by
diabetic conditionsmight be one of the reasons leading to the
decrease of L-VGCCs.
One potential caveat of this study is that while STZ
injections induced a significantly higher blood glucose level
in STZ-embryos compared to controls, the increase of the
plasma glucose level is not as high as what is observed in the
STZ-induced diabetic rodents (from ∼150mg/dL of controls
to ∼250–400mg/dL after STZ injections). We postulate that
the blood glucose level increased at a much higher rate in
8 Journal of Diabetes Research
rodents because animals used in themammalian STZ-animal
models already consume food with insulin- mediated blood
glucose regulation by the time of STZ injections. But chicken
embryos do not “eat,” and the pancreas has not yet fully
developed, so naturally, chicken embryos might not display a
large surge in blood glucose levels 1 week after STZ injections.
While STZ injections into the amnion layer induced diabetic
pathology in the chick embryonic eyes (cataract and other
pathophysiology of the retina), which is comparable to the
STZ-induced diabetic rodent models, we cannot completely
rule out the possibility that observed retinal pathology in
STZ-injected chicken embryos could potentially contribute
to the detrimental effects of developing retinas. Since STZ
injections often fail to induce diabetes in adult birds because
of species-dependence in STZ-sensitivity [23, 24], we hence
tried to induce diabetic conditions in chicken embryos.
Future research on the hatched/young adult STZ-chickens
will be needed to ensure the establishment of diabetes in adult
STZ-chickens, which will complement the existing animal
models for diabetic research and will further assist in treating
or preventing cone degeneration in human diabetic patients
in the future.
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